MedTrace Logo

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

NCT04982549 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-08-06

No results posted yet for this study

Summary

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

Conditions

  • Unresectable Stage III NSCLC

Interventions

DRUG

Durvalumab

Durvalumab (intravenous infusion)

DRUG

Carboplatin/ Paclitaxel

Carboplatin /Paclitaxel, as per standard of care

DRUG

Pemetrexed/ Cisplatin

Pemetrexed / Cisplatin, as per standard of care

DRUG

Pemetrexed/ Carboplatin

Pemetrexed / Carboplatin , as per standard of care

RADIATION

Radiation

5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2022-12-01
Completion
2023-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982549 on ClinicalTrials.gov